-
2024-510985-17-00
4
2019-03-14
First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive
-
2023-503812-34-00
4
2019-02-13
Locally Advanced or Metastatic Disease in Solid Tumors
-
2024-516628-32-00
5
2019-01-24
Multiple Sclerosis
-
2022-502937-24-00
5
2019-01-02
Atopic Dermatitis
-
2024-511850-34-00
9
2019-01-02
Previously untreated locally recurrent inoperable or metastatic triple
-
2024-510605-28-00
5
2018-11-27
Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
-
2023-505376-30-00
4
2018-10-30
BRAF V600 mutation–positive unresectable or metastatic melanoma
-
2022-501966-23-00
5
2018-09-11
Resected High-Risk Stage II Melanoma
-
2024-513206-65-00
5
2018-08-10
resected squamous cell carcinoma of head and neck
-
2024-510713-15-00
4
2018-07-30
Localised and operable soft tissue sarcomas
-
2023-505341-23-00
5
2018-07-27
Non-muscle invasive bladder cancer
-
2023-509976-40-00
5
2018-05-28
Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
-
2024-513027-16-00
4
2018-05-28
Resectable mucosal melanomas
-
2024-510913-13-00
10
2018-05-18
Previously Untreated Metastatic or Unresectable Melanoma
-
2023-509500-15-00
9
2018-05-03
Adult patients with advanced or metastatic solid tumors
-
2023-506429-13-00
5
2018-05-02
Progressive multiple sclerosis (PMS)
-
2023-509004-15-00
10
2018-02-20
Patients with non-small cell lung cancer (NSCLC).
-
2024-513070-21-00
4
2018-02-15
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-512470-10-00
11
2018-02-02
End-stage Renal disease
-
2024-516601-23-00
5
2017-11-14
Colorectal adenomas
-
2024-512789-32-00
5
2017-10-09
Unresectable or metastatic soft tissue sarcoma
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2023-507702-13-00
7
2017-09-22
Male or female patients age 12 years or older with a locally advanced
-
2024-513964-24-00
5
2017-09-14
Squamous cell carcinoma, previously untreated
Stage III, stage IVa (op